MetaCap

aTyr Pharma (ATYR) vs Black Hawk Acquisition (BKHA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

aTyr Pharma is the larger company by market cap ($9.7 million vs $7.7 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATYR+1272.62%BKHA-85.77%
+2759%+1269%-221%
Oct 7, 20261 yearNov 20, 2026
ATYR+1451.58%BKHA-83.95%
+2607%+1198%-212%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATYR versus BKHA key metrics
MetricATYRBKHA
Share price$3.82$1.85
Market cap$9.74M$7.68M
1-day change+3.52%-71.45%
YTD return+387.87%—
1-year return+474.44%—
5-year return-52.61%—
P/E ratio (TTM)—5.61
EPS (TTM)$-21.64$0.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$190.00K—
Revenue growth (YoY)-19.15%—
Net income (latest FY)$-74.12M$1.33M
Operating margin-40856.32%—
Net margin-39009.47%—
52-week high$44.40$23.00
52-week low$3.69$1.75
Distance from 52-week high-91.40%-91.96%
Analyst consensusbuy—
Avg. price target upside-25.13%—
Average volume115.38K101.40K
Shares outstanding2.55M4.15M
Employees58—
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About aTyr Pharma

ATYR stock →

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees

About Black Hawk Acquisition

BKHA stock →

Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

ATYR vs BKHA FAQ

Which is bigger, aTyr Pharma or Black Hawk Acquisition?

aTyr Pharma (ATYR) is larger, with a market capitalization of $9.74M compared with $7.68M for Black Hawk Acquisition (BKHA).

Are aTyr Pharma and Black Hawk Acquisition in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons